Peptides in the Limelight: US FDA May Ease Restrictions on Several Peptides The Dermatology Digest BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters PBS News A Note on Peptides by Shantanu Out of Singapore